| Literature DB >> 25070494 |
Q-B Lu1,2, Y Wo2, H-Y Wang2, D-D Huang2, J Zhao2, X-A Zhang2, Y-Y Zhang2, E-M Liu3, W Liu4, W-C Cao5.
Abstract
Human bocavirus (HBoV) is a novel parvovirus, often associated with respiratory tract diseases in children. This study explored the epidemiological characteristics and molecular evolution of HBoV-1 in southeastern China. Nasopharyngeal aspirates were collected from children admitted to hospital with acute respiratory tract infections. HBoV-1 was detected using real-time reverse transcription polymerase chain reaction and further characterized by complete genome sequences analysis. Among the 3,022 recruited children, 386 (12.77%) were HBoV-1-positive and 300 (77.72%) had co-detection with other respiratory viruses. Seasonal prevalence peaked in summer. HBoV-1 presence was significantly associated with asthma attack [odds ratio = 1.74; 95 % confidence interval: 1.30, 2.31; p < 0.001]. Similar results were obtained when either single detection or co-detection of HBoV-1 was considered, demonstrating the minor impact of co-detection on the clinical characteristics or epidemic pattern. Phylogenetic analysis based on the complete genome sequences showed that all the HBoV-1 sequences clustered together and no branch was formed that was supported by bootstrap value ≥ 750. The overall evolutionary rate of the complete genome of HBoV-1 was estimated at 1.08 × 10(-4) nucleotide substitutions per site per year (s/s/y) [95% highest probability density: (0.40-1.86) × 10(-4) s/s/y]. Selective pressure analysis showed that all the ω-values were less than 1, suggesting that HBoV-1 was under negative selective pressure. Site-by-site analysis identified the codon site 40 of the VP1 gene under positive selection. In conclusion, our study disclosed the epidemiological and genetic dynamics of HBoV-1 epidemics in southeastern China in the most recent 3 years, the information of which might help to further improve our understanding of HBoV-1 infection and guide better surveillance and control strategies in the future.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25070494 PMCID: PMC7087953 DOI: 10.1007/s10096-014-2215-7
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Distribution and clinical characteristics of HBoV-1 infections
| Factor | HBoV | Logistic regression model* | ||||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive vs negative | ||||
| Single | Coinfection |
| OR (95 % CI) |
| ||
| Age (months) | 86 | 300 | 0.286 | 2,636 | ||
| 0–6 | 20 (23.26) | 88 (2.91) | 1,154 (43.81) | 0.87 (0.60, 1.25) | 0.443 | |
| 7–12 | 23 (26.74) | 84 (28.00) | 513 (19.48) | 1.92 (1.32, 2.80) | <0.001 | |
| 13–24 | 30 (34.88) | 70 (23.33) | 361 (13.71) | 2.57 (1.75, 3.76) | <0.001 | |
| 25–36 | 5 (5.81) | 22 (7.33) | 199 (7.56) | 1.26 (0.76, 2.10) | 0.368 | |
| >36 | 8 (9.30) | 36 (12.00) | 407 (15.45) | 1.00 | ||
| Sex (male) | 51 (59.30) | 214 (71.33) | 0.034 | 1,751 (66.43) | 1.10 (0.88, 1.39) | 0.406 |
| Clinical manifestation | ||||||
| Cough | 83 (96.51) | 291 (97.00) | 0.818 | 2,495 (94.65) | 1.87 (1.02, 3.43) | 0.044 |
| Sputum | 63 (73.26) | 226 (75.33) | 0.695 | 1,997 (75.76) | 0.98 (0.76, 1.26) | 0.871 |
| Diarrhea | 26 (30.23) | 91 (30.33) | 0.986 | 794 (30.12) | 1.05 (0.82, 1.33) | 0.726 |
| Clinical diseases | ||||||
| URTI | 17 (19.77) | 81 (27.00) | 0.174 | 612 (23.22) | 1.13 (0.88, 1.46) | 0.335 |
| Bronchitis | 8 (9.30) | 13 (4.33) | 0.073 | 150 (5.69) | 0.94 (0.58, 1.51) | 0.788 |
| Pneumonia | 73 (84.88) | 269 (89.67) | 0.219 | 2,318 (87.94) | 1.05 (0.74, 1.48) | 0.791 |
| Asthma attack | 14 (16.28) | 61 (20.33) | 0.402 | 342 (12.97) | 1.74 (1.30, 2.31) | <0.001 |
| Wheeze | 34 (39.53) | 146 (48.67) | 0.135 | 1,159 (43.97) | 1.18 (0.94, 1.47) | 0.162 |
| Adverse outcome | ||||||
| Severe pneumonia | 12 (16.44) | 41 (15.24) | 0.946 | 397 (17.13) | 0.95 (0.69, 1.31) | 0.742 |
| Severe asthma | 2 (14.29) | 2 (3.28) | 0.216 | 21 (6.14) | 1.79 (0.54, 5.95) | 0.342 |
*The ORs were calculated by adjusting the variables of age, sex, and the infections of influenza virus, HAdV, RSV, PIV, MPV, COV, HRV, and HEV for the clinical manifestation, clinical diseases, and adverse outcome. Logistic regression analysis was applied with clinical disease as the dependent variable and HBoV-1 infection as the independent variable. Odds ratios (ORs) and their 95 % confidence intervals (CIs) were estimated using maximum likelihood method
Fig. 1Distribution of monthly positive rates of HBoV-1 infection during 2009–2012
Fig. 2Phylogenetic tree constructed based on 5,157 bp of the complete genome sequences of HBoV-1 with the neighbor-joining method using CLC Main Workbench 5.5. The strain name in this study began with CQ. HBoV-1 is represented by the black line, HBoV-2 by the blue line, HBoV-3 by the green line, and HBoV-4 by the red line
Estimated mean evolutionary rates of HBoV-1 and the four genes
| Gene | Mean evolutionary rate | 95 % HPD |
|---|---|---|
| NS | 8.43 × 10−5 | 3.45 × 10−8–2.58 × 10−4 |
| NP | 3.15 × 10−4 | (1.05–5.22) × 10−4 |
| VP1 | 1.94 × 10−4 | (0.79–2.99) × 10−4 |
| VP2 | 2.45 × 10−4 | (1.13–3.71) × 10−4 |
| Complete genome | 1.08 × 10−4 | (0.40–1.86) × 10−4 |
Selective pressure analysis on the four genes of HBoV-1 by four methods
| Gene | Model | Mean d | Positively selected site | |||
|---|---|---|---|---|---|---|
| SLAC | FEL | IFEL | FUBAR | |||
| NS | HKY85 | 0.16 (0.11–0.22) | Null | Null | Null | Null |
| NP | HKY85 | 0.23 (0.15–0.33) | Null | Null | Null | Codon 79 |
| VP1 | TrN93 | 0.11 (0.08–0.13) | Codon 40 | Codon 40 | Codon 40 | Codon 40 |
| VP2 | 010023 | 0.08 (0.06–0.10) | Null | Null | Null | Null |